small nucleolar RNA, C/D box 1BGenealiases: R38B · snR38B
Q-omics provides the consensus-scored SNORD1B profile across patient tissues and cancer cell-line models. SNORD1B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNORD1B is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SNORD1B RNA expression shows 14,440 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, and UVM as cancer lineages where SNORD1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD1B survival associations across molecular data types. SNORD1B RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD1B RNA expression–survival associations across cancer types. High SNORD1B expression shows unfavorable associations in COAD, LIHC, LGG, KIRP and KICH, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNORD1B RNA expression.
This table summarizes SNORD1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD1B shows lower tumor expression in THCA and higher tumor expression in COAD, READ, BLCA, STAD and HNSC. The COAD box plot shows higher SNORD1B RNA expression in tumor versus normal tissue (log2 FC = +0.632, t-test p < 0.001).
This table shows molecular features associated with SNORD1B in patient tissues and cancer cell lines. In patient samples, SNORD1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
